Patient-Friendly Explanation

Cotadutide is an investigational medication that mimics two natural hormones involved in appetite and metabolism. It is being studied for its potential to help with weight loss and improve liver health, particularly in people with fatty liver disease. It is given as a once-daily injection under the skin.

Clinical Definition

Cotadutide is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist under investigation for the treatment of non-alcoholic steatohepatitis (NASH) with fibrosis and obesity. By simultaneously activating GLP-1 receptors (reducing appetite and caloric intake) and glucagon receptors (increasing energy expenditure and hepatic lipid oxidation), cotadutide targets both sides of the energy balance equation with demonstrated reductions in liver fat content and body weight in Phase 2 clinical trials.

Why It Matters

Cotadutide represents an emerging class of weight management medications that target multiple metabolic pathways simultaneously. While not yet approved, it highlights the growing range of pharmaceutical options that may become available for medically supervised weight loss at NuLifeCare Singapore.